Directory
Portfolio companies.
34,000+ PE-backed.
Active investments and exits across European private equity portfolios.
Filter by sector, geography, status. Find the right deal comp in seconds.
Active deals
241
currently held
Exits tracked
163
hand-checked
Sectors covered
1
across the portfolio
Countries covered
36
from every market
Latest activity
BP Technology VenturesadminDirector Departure · Resignation of MORELAND, Jennifer Lynne (director) · director resigned · governance change5 days agoDirector Departure · Resignation of MORELAND, Jennifer Lynne (director) · director resigned · governance change
adminB.P. Marsh & PartnerscapitalCapital Event · capital-return-purchase-own-shares-treasury-capital-date · Capital structure change5 days agoCapital Event · capital-return-purchase-own-shares-treasury-capital-date · Capital structure change
capital
Arkea CapitaladminBoard change · Management board member change:: TRIDEAU Thomas, Jérôme · Change in the management board6 days agoBoard change · Management board member change:: TRIDEAU Thomas, Jérôme · Change in the management board
adminCaledonia InvestmentscapitalCapital Event · capital-cancellation-shares · Capital structure change6 days agoCapital Event · capital-cancellation-shares · Capital structure change
capitalCervinvest CapitaladminCEO change · Appointment of CEO De Jongh, Guillaume · New CEO appointed1 week agoCEO change · Appointment of CEO De Jongh, Guillaume · New CEO appointed
adminCervinvest CapitaladminChairman change · Appointment of Chairman Radix, Maxence. Departure of CEO Rouland, Antoine · New Chairman appointed. CEO departure · leadership transition underway1 week agoChairman change · Appointment of Chairman Radix, Maxence. Departure of CEO Rouland, Antoine · New Chairman appointed. CEO departure · leadership transition underway
admin330 companies matching · Page 2 of 7
Minafin
QCP Buyout Fund III
FranceSector
Pharma
InvestorQuilvest Capital Partners
Entry
2011
Hold
9yr
Owners
6
iNova
TPG Europe Portfolio
Australia
Sector
Pharma
InvestorTPG Europe
Entry
2021
Hold
5yr
Owners
2
Arcinova
BGF
UKSector
Pharma
InvestorBGF
Entry
2018
Hold
3yr
Exit
2021
to Quotient Sciences
Audevard
Ekkio Capital IV
FranceSector
Pharma
InvestorEkkio Capital
Entry
2015
Hold
6yr
Exit
2021
to LIM Group
Curapath
Columbus Innvierte Life Science Fund I
SpainSector
Pharma
InvestorColumbus Venture Partners
Entry
2017
Hold
4yr
Exit
2021
to Arcline Investment Management
HRA Pharma
Astorg VI
FranceSector
Pharma
InvestorAstorg
Entry
2016
Hold
5yr
Exit
2021
to Perrigo Company
Suanfarma
Direct investment by Peugeot Invest
HQ Spain / Global presence
Sector
Pharma
InvestorPeugeot Invest
Entry
2015
Hold
5yr
Owners
4
Sygnature Discovery
Five Arrows Principal Investments
UKSector
Pharma
InvestorFive Arrows Managers
Entry
2019
Hold
5yr
Owners
3
Cooper
CVC Capital Partners Fund VII
UKSector
Pharma
InvestorCVC Capital Partners
Entry
2015
Hold
6yr
Owners
2
3.0x
Pharmathen
Partners Group Direct Equity IV
Greece
Sector
Pharma
InvestorPartners Group
Entry
2015
Hold
6yr
Owners
2
Fertin Pharma
EQT Mid Market Europe
DenmarkSector
Pharma
InvestorEQT
Entry
2017
Hold
4yr
Exit
2021
to Philip Morris International
Idifarma
Sodena Direct
SpainSector
Pharma
InvestorSodena
Entry
2006
Hold
15yr
Exit
2021
to Ardena
OHRE Pharma
Vatel Capital
FranceSector
Pharma
InvestorVATEL CAPITAL
Entry
2018
Hold
3yr
Exit
2021
to Strategic Generics France
Pharmaceutical Product Development, Inc. (PPD)
Carlyle Partners V, L.P.
USASector
Pharma
InvestorThe Carlyle Group
Entry
–
Exit
2021
to Thermo Fisher Scientific
Sunsho Pharmaceutical Co., Ltd.
The Carlyle Group Portfolio
Japan
Sector
Pharma
InvestorThe Carlyle Group
Entry
–
Exit
2021
to Towa Pharmaceutical
Xeris Biopharma Holdings, Inc (Strongbridge)
HealthCap VI
United StatesSector
Pharma
InvestorHealthCap
Entry
2014
Hold
7yr
Exit
2021
to Xeris Pharmaceuticals
Neuraxpharm
CM-CIC Debt Fund 3
GermanySector
Pharma
InvestorCIC Private Debt
Entry
2016
Hold
6yr
Owners
3
3.5x
Axpharma
FPCI Galiena III
FranceSector
Pharma
InvestorGaliena Capital
Entry
2015
Hold
5yr
Exit
2020
to ProductLife Group (backed by 21 Invest)
PharmaZell
Europe VI (BE VI)
GermanySector
Pharma
InvestorBridgepoint
Entry
2006
Hold
6yr
Owners
4
Cobra Biologics
Flerie Invest
United KingdomSector
Pharma
InvestorFlerie
Entry
2011
Hold
9yr
Exit
2020
to Cognate BioServices
Farma Holding
PCI IV
NorwaySector
Pharma
InvestorProcuritas Capital Investors
Entry
2011
Hold
9yr
Exit
2020
to Management and PK Partners
OFI
Alto Capital IV
ItalySector
Pharma
InvestorAlto Partners SGR
Entry
2019
Hold
1yr
Exit
2020
to Farmaceutici Procemsa
Riemser
Ardian Buyout Fund V
GermanySector
Pharma
InvestorArdian
Entry
2012
Hold
8yr
Exit
2020
to Esteve
Shenghuo
Cathay Capital Midcap I
China
Sector
Pharma
InvestorCathay Capital
Entry
2014
Hold
6yr
Exit
2020
to China Resources Sanjiu Medical & Pharmaceutical
KD Pharma
capiton Omega
GermanySector
Pharma
Investorcapiton
Entry
2013
Hold
7yr
Owners
2
Fagron
Waterland Private Equity Fund VI (WPEF VI)
BelgiumSector
Pharma
InvestorWaterland Private Equity
Entry
2016
Hold
3yr
Exit
2019
Quotient Sciences
Permira VII
UKSector
Pharma
InvestorPermira
Entry
2015
Hold
7yr
Owners
2
Ascelia Pharma
Sunstone Life Science Ventures III
SwedenSector
Pharma
InvestorSunstone Life Science Ventures
Entry
2008
Hold
11yr
Exit
2019
Aurka Pharma, Inc.
TVM Life Science Ventures
Canada
Sector
Pharma
InvestorTVM Capital Life Science
Entry
2016
Hold
3yr
Exit
2019
to Eli Lilly
Lisapharma
Arcadia Small Cap I
ItalySector
Pharma
InvestorArcadia SGR
Entry
2015
Hold
4yr
Exit
2019
to Shandong Sito Bio-Technology
Lomapharm
Lenbach Equity Opportunities I
GermanySector
Pharma
InvestorDUBAG Group
Entry
2013
Hold
5yr
Exit
2018
to Daicel Corporation
CYCLOPHARMA
SGCP Evergreen (balance sheet)
FranceSector
Pharma
InvestorSociete Generale Capital Partenaires
Entry
2007
Hold
11yr
Exit
2018
to Curium
Wilson Therapeutics AB
HealthCap VI
SwedenSector
Pharma
InvestorHealthCap
Entry
2012
Hold
6yr
Exit
2018
to Alexion Pharmaceuticals
XERIS Pharmaceuticals
Mérieux Innovation 1
USSector
Pharma
InvestorMerieux Equity Partners
Entry
2017
Hold
1yr
Exit
2018
to Nasdaq listing (XERS)
Unither Pharmaceuticals
IK Partnership Fund II
FranceSector
Pharma
InvestorIK Partners
Entry
2011
Hold
9yr
Owners
4
EA PHARMA (GROUPE)
Naxicap Legacy Funds
FranceSector
Pharma
InvestorNaxicap Partners
Entry
2006
Hold
11yr
Exit
2017
Generis
Magnum Capital I
PortugalSector
Pharma
InvestorMagnum Capital
Entry
2009
Hold
8yr
Exit
2017
to Aurobindo Pharma
Actelion
Wellington Partners Life Sciences
FranceSector
Pharma
InvestorWellington Partners
Entry
1998
Hold
19yr
Owners
2
Exit
2017
to Johnson & Johnson
Actelion Holding Ltd
HealthCap (early funds)
SwitzerlandSector
Pharma
InvestorHealthCap
Entry
1997
Hold
20yr
Exit
2017
to Johnson & Johnson
ALIZÉ PHARMA SAS
Capital Santé 2
FranceSector
Pharma
InvestorTurenne Groupe
Entry
2014
Hold
3yr
Exit
2017
to Millendo Therapeutics
CoLucid Pharmaceuticals
TVM Life Science Ventures
United StatesSector
Pharma
InvestorTVM Capital Life Science
Entry
2015
Hold
2yr
Exit
2017
to Eli Lilly
Isochem
AURELIUS Opportunities V
FranceSector
Pharma
InvestorAURELIUS
Entry
2010
Hold
7yr
Exit
2017
to PMC Group
Tridem Pharma
Paluel-Marmont Capital Fund
FranceSector
Pharma
InvestorPaluel-Marmont Capital
Entry
2011
Hold
6yr
Exit
2017
to Fosun Pharma
Seqens
CM-CIC Debt Fund 3
FranceSector
Pharma
InvestorCIC Private Debt
Entry
2011
Hold
10yr
Owners
6
Italchimici
Progressio Investimenti II
ItalySector
Pharma
InvestorProgressio SGR
Entry
2015
Hold
1yr
Owners
2
Exit
2016
to Recordati3.0x
PHYSICA PHARMA
Galia Investissements I
FranceSector
Pharma
InvestorGalia Gestion
Entry
2004
Hold
12yr
Exit
2016
to Unither Pharmaceuticals
Euticals
Private Equity Partners Fund IV
ItalySector
Pharma
InvestorPrivate Equity Partners
Entry
2008
Hold
4yr
Owners
3
Exit
2016
to AMRI
Zytoservice
IK VIII (Mid Cap)
GermanySector
Pharma
InvestorIK Partners
Entry
2008
Hold
10yr
Owners
2
AB7 HOLDING
SGCP Evergreen (balance sheet)
FranceSector
Pharma
InvestorSociete Generale Capital Partenaires
Entry
2007
Hold
9yr
Exit
2016
ADVANCED ACCELERATOR APPLICATIONS
Naxicap Legacy Funds
FranceSector
Pharma
InvestorNaxicap Partners
Entry
2008
Hold
8yr
Exit
2016
to Novartis AG